The year in interventional cardiology

Journal of the American College of Cardiology

Volumn 57, Issue 22, 2011, Pages 2207-2220

  Dixon, Simon R ^a   Grines, Cindy L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

percutaneous intervention; review; stent; TAVI

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ATORVASTATIN; BICARBONATE; CILOSTAZOL; CLOPIDOGREL; CYCLOSPORIN; ELINOGREL; ENOXAPARIN; EPTIFIBATIDE; ERYTHROPOIETIN; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID ESTER; PACLITAXEL; PRASUGREL; PROTON PUMP INHIBITOR; RAPAMYCIN; TICAGRELOR; TIROFIBAN; WARFARIN; ZOTAROLIMUS;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AORTA BIFURCATION; AORTA STENOSIS; AORTA VALVE REPLACEMENT; AORTIC VALVE REPAIR; BARE METAL STENT; BLEEDING; CARDIOGENIC SHOCK; CARDIOLOGY; CAROTID ARTERY DISEASE; CAROTID ARTERY STENTING; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENTIATION; ECHOCARDIOGRAPHY; ENDOVASCULAR ANEURYSM REPAIR; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYDRATION; INTRACORONARY ROUTE; INTRAVASCULAR ULTRASOUND; KIDNEY DENERVATION; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL LITERATURE; MITRAL VALVE REPAIR; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATENT FORAMEN OVALE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RESTENOSIS; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; STENT THROMBOSIS; STROKE; SURGICAL APPROACH; SURGICAL TECHNIQUE; THROMBECTOMY; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; VASCULAR ACCESS;

EID: 79957563075     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.01.027     Document Type: Review

References (143)

1. M.B. Leon, C.R. Smith, and M. Mack Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery N Engl J Med 363 2010 1597 1607
2. R. Gurvitch, D.A. Wood, and E.L. Tay Transcatheter aortic valve implantation Durability of clinical and hemodynamic outcomes beyond 3 years in a large cohort Circulation 122 2010 1319 1327
3. M. Pasic, A. Unbehaun, and S. Dreysse Transapical aortic valve implantation in 175 consecutive patients Excellent outcomes in very high-risk patients J Am Coll Cardiol 56 2010 813 820
4. J. Rods-Cabau, J.G. Webb, and A. Cheung Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk Acute and late outcomes of the multicenter Canadian experience J Am Coll Cardiol 55 2010 1080 1090
5. C. Godino, F. Maisano, and M. Montorfano Outcomes after transcatheter aortic valve implantation with both Edwards-SAPIEN and CoreValve devices in a single center: the Milan experience J Am Coll Cardiol Intv 3 2010 1110 1121
6. M. Thomas, G. Schymik, and T. Walther Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry A European registry of the transcatheter aortic valve implantation using the Edwards SAPIEN valve Circulation 122 2010 62 69
7. M.A. Clavel, J.G. Webb, and J. Rods-Cabau Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction Circulation 122 2010 1928 1936
8. D. Messika-Zeitoun, J.M. Sefaty, and E. Brochet Multimodal assessment of the aortic annulus diameter Implications for transcatheter aortic valve implantation J Am Coll Cardiol 55 2010 186 194
9. M.A. Sherif, M. Abdel-Wahab, and B. Stcker Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis J Am Coll Cardiol 56 2010 1623 1629
10. A. Ghanem, A. Mller, and C.P. Nhle Risk and fate of cerebral embolism after transfemoral aortic valve implantation J Am Coll Cardiol 55 2010 1427 1432
11. P. Kahlert, S.C. Knipp, and M. Schlamann Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation A diffusion-weighted magnetic resonance imaging study Circulation 121 2010 870 878
12. Feldman T. EVEREST II. Endovascular valve edge-to-edge repair study (EVEREST II) randomized clinical trial: primary safety and efficacy endpoints. Paper presented at: Annual Meeting of American College of Cardiology; March 14, 2010; Atlanta, GA.
13. Furlan A. CLOSURE I. A prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the STARFlex Septal Closure System versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Paper presented at: Annual Meeting of American Heart Association; November 15, 2010; Chicago, IL.
14. B.J. van den Branden, M.C. Post, and H.W. Plokker Patent foramen ovale closure using a bioabsorbable closure device: safety and efficacy at 6-month follow-up J Am Coll Cardiol Intv 3 2010 968 973
15. W.J. Zimmermann, C. Heinisch, and N. Majunke Patent foramen ovale closure with the SeptRx device: initial experience with the first "in-tunnel" device J Am Coll Cardiol 3 2010 963 967
16. D.W. Park, K.B. Seung, and Y.H. Kim Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease J Am Coll Cardiol 56 2010 117 124
17. D.W. Park, Y.H. Kim, and S.C. Yun Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease J Am Coll Cardiol 56 2010 1366 1375
18. A. Cheiffo, V. Magni, and A. Latib 5-Year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions: the Milan experience J Am Coll Cardiol Intv 3 2010 595 601
19. M.C. Morice, P.W. Serruys, and A.P. Kappetein Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial Circulation 121 2010 2645 2653
20. Serruys PW. The Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX): the 3-year outcomes of the SYNTAX trial in the subset of patients with left main disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 21, 2010; Washington, DC.
21. A.P. Banning, S. Westaby, and M.C. Morice Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease Comparison of outcomes with cardiac surgery and paclitaxel-eluting stents J Am Coll Cardiol 55 2010 1067 1075
22. W. Hueb, N. Lopes, and B.J. Gersh Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease Circulation 122 2010 949 957
23. A. Kapur, R.J. Hall, and I.S. Malik Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial J Am Coll Cardiol 55 2010 432 440
24. P.W. Serruys, Y. Onuma, and S. Garg 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions J Am Coll Cardiol 55 2010 1093 1101
25. Mohr FW. The Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX): the 3-year outcomes of the SYNTAX trial in the subset of patients with threevessel disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 21, 2010; Washington, DC.
26. P.A.L. Tonino, W.F. Fearon, and B. De Bruyne Angiographic versus functional severity of coronary artery stenoses in the FAME study J Am Coll Cardiol 55 2010 2816 2821
27. N.H.J. Pijls, W.F. Fearon, and P.A.L. Tonino Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) study J Am Coll Cardiol 56 2010 177 184
28. D. Hildick-Smith, A.J. de Belder, and N. Cooter Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions The British Bifurcation Coronary Study: old, new and evolving strategies Circulation 121 2010 1235 1243
29. Y.B. Song, J.Y. Hahn, and S.H. Choi Sirolimus-eluting versus paclitaxel-eluting stents for the treatment of coronary bifurcations Results from the COBIS (Coronary Bifurcation Stenting) registry J Am Coll Cardiol 55 2010 1743 1750
30. H.J. Colmenarez, J. Escaned, and C. Fernandez Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization A systematic review and meta-analysis J Am Coll Cardiol 55 2010 1854 1866
31. D. Perera, R. Stables, and M. Thomas Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial JAMA 304 2010 867 874
32. M.R. Petal, H. Jneid, C.P. Derdeyn American Heart Association Diagnostic and Interventional Cardiac Catheterization Committee of the Council on Clinical Cardiology, Council on Cardiovascular Radiology and Intervention, Council on Peripheral Vascular Disease, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association Circulation 122 2010 1882 1893
33. A.H. Seto, M.S. Abu-Fadel, and J.M. Sparling Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial) J Am Coll Cardiol Intv 3 2010 751 758
34. Kim YK. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography: the PREVENT trial. Paper presented at: Annual Meeting of American College of Cardiology; March 14, 2010; Atlanta, GA.
35. Bartorelli AL. Furosemide-induced high-volume diuresis with matched hydration using a dedicated device to prevent contrast nephropathy. The MYTHOS trial. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 22, 2010; Washington, DC.
36. H. Thiele, L. Hildebrand, and C. Schirdewahn Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention J Am Coll Cardiol 55 2010 2201 2209
37. ACT Investigators. Acetylcysteine for the prevention of contrastinduced nephropathy (ACT) trial. Paper presented at: Annual Meeting of American Heart Association; November 16, 2010; Chicago, IL.
38. Colombo A. AVIO: a prospective, randomized trial of intravascularultrasound guided compared with angiography guided stent implantation in complex coronary lesions. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
39. C. Kaiser, S. Galatius, and P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319
40. A. Latib, L. Ferri, and A. Ielasi Comparison of the long-term safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts Circ Cardiovasc Interv 3 2010 249 256
41. D.R. Holmes, D.J. Kereiakes, and S. Garg Stent thrombosis J Am Coll Cardiol 56 2010 1357 1365
42. T. Kimura, T. Morimoto, and K. Kozuma Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) Circulation 122 2010 52 61
43. L. Rber, P. Jni, and L. Lffel Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation J Am Coll Cardiol 55 2010 1178 1188
44. M.B. Leon, L. Lauri, and J.J. Popma A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
45. M.B. Leon, E. Nikolsky, and D.E. Cutlip Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions J Am Coll Cardiol Intv 3 2010 1043 1050
46. D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent With Sirolimus-Eluting and Paclitaxel-Eluting Stent for Coronary Lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
47. K. Rasmussen, M. Maeng, and A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomized controlled superiority trial Lancet 375 2010 1090 1099
48. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
49. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomized trial Lancet 375 2010 201 209
50. Smits P. COMPARE trial 2-year follow-up. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 23, 2010; Washington, DC.
51. Ribichini F. A prospective, randomized trial comparing an everolimus-eluting stent and a paclitaxel-eluting stent in patients with multivessel coronary artery disease. The EXECUTIVE study. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 21, 2010; Washington, DC.
52. Kim H. Efficacy of Xience/Promus versus Cypher to reduce late loss in stent (EXCELLENT). Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
53. Byrne RA. Two-year outcomes after everolimus- or sirolimus-eluting stents in patients with coronary artery disease in the ISAR-TEST 4 trial. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
54. Jensen LO. A prospective, randomized trial of everolimus-eluting and sirolimus-eluting stents in patients with coronary artery disease. The SORT OUT IV trial. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
55. Raber L. LESSON-I. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. Paper presented at: Annual Meeting of European Society of Cardiology 2010 Congress; September 1, 2010; Stockholm, Sweden.
56. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
57. M. Abe, T. Kimura, and T. Morimoto Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: insights from the j-Cypher registry Circulation 122 2010 42 51
58. J. Mehilli, R.A. Byrne, and K. Tiroch Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis 2) study J Am Coll Cardiol 55 2010 2710 2716
59. Chevalier B. CRISTAL. A prospective randomized trial of sirolimuseluting stents compared with balloon angioplasty for restenosis of drug-eluting coronary stents. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
60. R.A. Byrne, A. Kastrati, and K. Tiroch 2-Year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
61. Mehilli J. ISAR-TEST 5: randomized, non-inferiority trial of rapamycin/probucol- and zotarolimus-eluting stents. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
62. Grube E. BioFreedom. A prospective randomized trial of polymerfree biolimus A9-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
63. D.J. Kereiakes, L.A. Cannon, and R.L. Feldman Clinical and angiographic outcomes after treatment of de novo coronary stenosis with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial J Am Coll Cardiol 56 2010 264 271
64. Whrle J. A prospective, randomized trial evaluation a paclitaxeleluting balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease (PERfECT STENT study). Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 23, 2010; Washington, DC.
65. M.A.M. Beijk, M. Klomp, and N.J.W. Verouden Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesion with a high-risk of coronary restenosis: a randomized, single-centre, pilot study Eur Heart J 31 2010 1055 1064
66. P.W. Serruys, Y. Onuma, and J.A. Ormiston Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis Six-month clinical and imaging outcomes Circulation 122 2010 2301 2312
67. B.R. Brodie, B.J. Gersh, and T. Stuckey When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial J Am Coll Cardiol 56 2010 407 413
68. L. Lambert, K. Brown, and E. Segal Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction JAMA 303 2010 2148 2155
69. C.J. Terkelsen, J.T. Sørensen, and M. Maeng System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention JAMA 304 2010 763 771
70. Stone GW. A prospective, multicenter randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin, and drug-eluting vs. bare metal stents in ST-segment elevation myocardial infarction. Final report from the HORIZONS-AMI trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 25, 2010; Washington, DC.
71. A. Kaltoft, H. Kelbæk, and L. Thuesen Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction 3-Year follow-up of the Randomized DEDICATION (Drug Eluting and Distal Protection in Acute Myocardial Infarction) trial J Am Coll Cardiol 56 2010 641 645
72. R. Violini, C. Musto, and F. De Felice Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-Year results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction) trial J Am Coll Cardiol 55 2010 810 814
73. Vink MA. Five year follow-up after primary PCI with a paclitaxeleluting stent versus a bare-metal stent in acute ST-elevation myocardial infarction. Paper presented at: Annual Meeting of American College of Cardiology; March 16, 2010; Atlanta, GA.
74. A. Kaltoft, H. Kelbæk, and L. Kløvgaard Increased rate of stent thrombosis and target lesion revascularization after filter protection in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: 15-month follow-up of the DEDICATION (Drug Eluting and Distal Protection in ST Elevation Myocardial Infarction) trial J Am Coll Cardiol 55 2010 867 871
75. N.G. Guo, A. Maehara, and G.S. Mintz Incidence, mechanism, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction An intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial Circulation 122 2010 1077 1084
76. P.L. Snchez, F. Gimeno, and P. Ancillo Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial Circ Cardiovasc Interv 3 2010 297 307
77. G.W. Stone, H. Parise, and B. Witzenbichler Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J Am Coll Cardiol 56 2010 1597 1604
78. A. Migliorini, A. Stabile, and A.E. Rodriguez Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction The JETSTENT trial J Am Coll Cardiol 56 2010 1298 1306
79. F.P. Mongeon, P. Blisle, and L. Joseph Adjunctive thrombectomy for acute myocardial infarction A Bayesian meta-analysis Circ Cardiovasc Interv 3 2010 6 16
80. Rao S. A randomized, double-blind, placebo-controlled trial of intravenous erythropoietin in patients with ST-segment elevation myocardial infarctionprimary results of the REVEAL trial. Paper presented at: Annual Meeting of American Heart Association; November 16, 2010; Chicago, IL.
81. A.A. Voors, A.M.S. Belonje, and H.L. Hillege A single dose of erythropoietin in ST-elevation myocardial infarction Eur Heart J 31 2010 2593 2600
82. I. Ott, S. Schulz, and J. Mehilli Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention A randomized, double-blind trial Circ Cardiovasc Interv 3 2010 408 413
83. N. Mewton, P. Croisille, and G. Gahide Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction J Am Coll Cardiol 55 2010 1200 1205
84. H.E. Bøtker, M.R. Kharbanda, and M. Bøttcher Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction Lancet 375 2010 727 734
85. J. Lønberg, H. Kelbæk, and N. Vejlstrup Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance Circ Cardiovasc Interv 3 2010 34 41
86. E. Bohmer, P. Hoffmann, and M. Abdelnoor Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances: results of the NORDISTEMI (Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction) J Am Coll Cardiol 55 2010 102 110
87. F. Borgia, S.G. Goodman, and S. Halvorsen Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis Eur Heart J 31 2010 2156 2169
88. P.H. Nielsen, M. Maeng, and M. Busk Primary angioplasty versus fibrinolysis in acute myocardial infarction Long-term follow-up in the Danish Acute Myocardial Infarction 2 trial Circulation 121 2010 1484 1491
89. M. Abdel-Wahab, M. Saad, and J. Kynast Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complication acute myocardial infarction Am J Cardiol 105 2010 967 971
90. K.A.A. Fox, T.C. Clayton, and P. Damman Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndromes A meta-analysis of individual patient data J Am Coll Cardiol 55 2010 435 445
91. P. Damman, A. Hirsch, and F. Windhausen 5-year clinical outcomes in the ICTUS (Invasive Versus Conservative Treatment in Unstable coronary Syndromes) trial J Am Coll Cardiol 55 2010 858 864
92. P. Sorajja, B.J. Gersh, and D.A. Cox Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management Analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 55 2010 1416 1424
93. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
94. G. Di Sciascio, G. Patti, and V. Pasceri High-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized trial J Am Coll Cardiol 56 2010 550 557
95. G. Di Sciascio, G. Patti, and V. Pasceri Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized trial Eur Heart J 31 2010 1337 1343
96. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard dose clopidogrel and high-dose versus low dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial Lancet 376 2010 1233 1243
97. Price M. GRAVITAS. Primary results of the gauging responsiveness with a VerifyNow assayimpact on thrombosis and safety trial. Paper presented at: Annual Meeting of American Heart Association; November 17, 2010; Chicago, IL.
98. D. Sibbing, J. Stegherr, and S. Braun A double-blind randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment J Am Coll Cardiol 55 2010 558 565
99. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
100. J.L. Mega, T. Simon, and J.P. Collet Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI : a meta-analysis JAMA 304 2010 1821 1830
101. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
102. L. Bonello, S. Armero, and O.A. Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 (*)2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
103. D. Sibbing, Koch, and D. Gebhard Cytochrome 2C19 (*)17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
104. J.L. Mega, S.L. Close, and S.D. Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
105. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 56 2010 2051 2066
106. J.L. Ferreiro, M. Ueno, and D. Capodanno Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake Results of a prospective randomized crossover study Circ Cardiovasc Interv 3 2010 436 441
107. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
108. G. Gajos, P. Rostoff, A. Undas, and W. Piwowarska Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study J Am Coll Cardiol 55 2010 1671 1678
109. Y.H. Jeong, J.Y. Hwang, and I.S. Kim Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction Results of the adjunctive cilostazol versus high maintenance dose clopidogrel inpatients with AMI (ACCEL-AMI) study Circ Cardiovasc Interv 3 2010 17 26
110. E.M. Mahoney, K. Wang, and S.V. Arnold Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention Circulation 121 2010 71 79
111. C.P. Cannon, R.A. Harrington, and S. James Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study Lancet 375 2010 283 293
112. P. Steg, S. James, and R.A. Harrington Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
113. S. James, A. Budaj, and P. Aylward Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 122 2010 1056 1067
114. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
115. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies The RESPOND study Circulation 121 2010 1188 1199
116. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
117. A. Bellemain-Appaix, D. Brieger, and F. Beygui New P2Y12 inhibitors versus clopidogrel in percutaneous intervention: a meta-analysis J Am Coll Cardiol 56 2010 1542 1551
118. Rao S. INNOVATE-PCI. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs. clopidogrel, as a novel antiplatelet therapy in patients undergoing non-urgent percutaneous coronary intervention. Paper presented at: Annual Meeting of European Society of Cardiology 2010 Congress; August 30, 2010; Stockholm, Sweden.
119. U. Zeymer, A. Margenet, and M. Haude Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment myocardial infarction Results of the EVA-AMI trial J Am Coll Cardiol 56 2010 463 469
120. A. kerblom, S.K. James, and M. Koutouzis Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) J Am Coll Cardiol 56 2010 470 475
121. J.M. Ten Berg, A.W.J. van't Hof, and T. Dill Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome J Am Coll Cardiol 55 2010 2446 2455
122. M. Valgimigli, G. Biondi-Zoccai, and M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2010 35 49
123. A.J. Deibele, L.K. Jennings, and J.E. Tcheng Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function The Intracoronary Eptifibatide (ICE) trial Circulation 121 2010 784 791
124. Y.L. Gu, M.A. Kampinga, and W.G. Wieringa Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration Circulation 122 2010 2709 2717
125. Montalescot G, Cohen M, Goldstein P, et al. ATOLL. An international randomized study comparing IV enoxaparin to IB UFH in primary PCI. Paper presented at: Annual Meeting of European Society of Cardiology 2010 Congress; August 30, 2010; Stockholm, Sweden.
126. S.V. Rao, C. Melloni, and S. Myles-DiMauro Evaluation of a new heparin agent in percutaneous coronary intervention Results of the phase 2 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) trial Circulation 121 2010 1713 1721
127. The FUTURA-OASIS-8 Trial Group Low-dose vs. standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux The FUTURA-OASIS-8 randomized trial JAMA 304 2010 1339 1349
128. J.S. Kim, J. Kim, and D. Choi Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial J Am Coll Cardiol Intv 3 2010 332 339
129. D.E. Winchester, X. Wen, L. Xie, and A.A. Bavry Evidence of pre-procedural statin therapy A meta-analysis of randomized trials J Am Coll Cardiol 56 2010 1099 1109
130. Esler MD. Symplicity HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Paper presented at: Annual Meeting of American Heart Association; November 27, 2010; Chicago, IL.
131. T.G. Brott, R.W. Hobson, and G. Howard Stenting versus endarterectomy for treatment of carotid stenosis N Engl J Med 363 2010 11 23
132. International Carotid Stenting Study Investigators Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial Lancet 375 2010 985 997
133. Carotid Stenting Trialists Collaboration Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data Lancet 376 2010 1062 1073
134. S. Bangalore, D.L. Bhatt, and J. Rther Late outcomes after carotid stenting versus carotid endarterectomy Insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) registry Circulation 122 2010 1091 1100
135. E. Stabile, L. Salemme, and G. Sorropago Proximal endovascular occlusion for carotid artery stenting: results from a prospective registry of 1,300 patients J Am Coll Cardiol 55 2010 1661 1667
136. T.L. Schreiber, N. Strickman, and T. Davis Carotid artery stenting with emboli protection surveillance study Outcomes at 1 year J Am Coll Cardiol 56 2010 49 57
137. The United Kingdom EVAR Trial Investigators Endovascular versus open repair of abdominal aortic aneurysm N Engl J Med 362 2010 1863 1871
138. The United Kingdom EVAR Trial Investigators Endovascular repair of aortic aneurysm in patients physically ineligible for open repair N Engl J Med 362 2010 1872 1880
139. J.R. Laird, B.T. Katzen, and D. Scheinert Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery Twelve-month results from the RESILIENT randomized trial Circ Cardiovasc Interv 3 2010 267 276
140. Scheinert D. LEVANT trial. A comparison of the Moxy drug coated balloon catheter vs. standard PTA for femoropopliteal disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 23, 2010; Washington, DC.
141. Dake MD. The Zilver PTX randomized trial: 12-month results of a paclitaxel-eluting stent versus balloon angioplasty and bare metal stenting in patients with femoropopliteal artery disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
142. Zeller T. DES-BTK. A prospective, double-blind randomized trial of polymer-free sirolimus-eluting stents compared with bare metal stents in patients with infrapopliteal disease. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
143. A.J. Feiring, M. Krahn, and L. Nelson Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PARADISE (Preventing Amputations Using Drug-Eluting Stents) trial J Am Coll Cardiol 55 2010 1580 1589